Press Contact: Kirsten Mabry | (617) 495-4157
Featured Tags:
December 11th, 2024
Novo Nordisk and Evotec selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases.
November 12th, 2024
‘Shrink it and pink it’ is not the answer. Harvard Grid hosts a panel on the lack of female representation in athletic product design.
October 28th, 2024
With funding and support from the Climate and Sustainability Translational Fund, researchers will pursue green jet fuel, cleaner chemicals, sustainable packaging, and carbon storage.
October 2nd, 2024
Attivare Therapeutics, a Harvard startup out of the Wyss Institute, has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS), Dana-Farber Cancer Institute, and Massachusetts General Hospital. This technology creates an in vivo training ground for the immune system to fight cancer more effectively and prevent infection.
September 19th, 2024
GC Therapeutics (GCTx), a Harvard startup, announced its launch to scale and its technology TFome™, the world’s first “plug and play” induced pluripotent stem cell (iPSC) programming platform for cell therapies in multiple therapeutic areas.
